Tomoko Yamazaki

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Lenvatinib for Anaplastic Thyroid Cancer

Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki et al. · Frontiers in Oncology · 2017 · 192 citations · Full text

Medicine, Oncology, Pharmacology +12

Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study

Naoshi Horikawa, Tomoko Yamazaki, Namiki Izumi et al. · General Hospital Psychiatry · 2003 · 142 citations

Medicine, Internal Medicine, Psychiatry +14

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial

Tomoko Yamazaki, Andrew J. Gunderson, Miranda Gilchrist et al. · The Lancet Oncology · 2022 · 142 citations

Medicine, Oncology, Surgery +16